PFO
CDAK

Pathstone Family Office’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Pathstone Family Office’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change % 		Capital Flow Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,000
Closed -$2.97K – 1323
2023
Q1 		$2.97K Sell
17,000
-13,000
-43% -$2.27K ﹤0.01% 1183
2022
Q4 		$11.9K Buy
30,000
+6,000
+25% +$2.39K ﹤0.01% 1472
2022
Q3 		$18.4K Buy
24,000
+14,000
+140% +$10.7K ﹤0.01% 1445
2022
Q2 		$28.8K Buy
+10,000
New +$28.8K ﹤0.01% 1026